Hospitalization in Patients with Psoriasis: Impact of Biological Therapies on Temporal Evolution
| Autor: | Alessia Ruibal Pereira, María Teresa Abalde, Virginia Fernández-Redondo, Queila Rodríguez-Jato, Crisitina Martinez-Reglero, Laura Salgado-Boquete, Ángeles Flórez, Ana Batalla |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty MEDLINE Disease Severity of Illness Index Biological drugs Psoriasis Extensive data Medicine Humans In patient Aged Retrospective Studies Biological therapies Biological Products business.industry General Medicine Middle Aged medicine.disease Hospitalization Cross-Sectional Studies Emergency medicine Population study Regression Analysis Female business |
| Zdroj: | Journal of drugs in dermatology : JDD. 20(2) |
| ISSN: | 1545-9616 |
| Popis: | Background Psoriasis is an immunomediated disease mostly controlled at the outpatient level, although there is a low percentage of patients that require systemic drugs or even hospitalization for an adequate control. Biological drugs have represented a turning point in its treatment. So far, despite the growing interest in psoriasis and its management with biological therapies, there is a lack of studies focusing on their impact on hospitalization, a relevant issue to patients and to the sustainability of our healthcare system. Objective In this study, we aimed to describe the temporal evolution of the hospitalizations of patients with psoriasis throughout the period between eight years before the commercialization of the first biological drugs and present, and secondly, whether this market irruption was related to a decrease in the number of admissions. Methods Data was collected retrospectively from the Dermatology department of the Complexo Hospitalario Universitario de Ponte- vedra (CHUP) including patients of all ages with a diagnosis of psoriasis and at least one admission to the department of Dermatology along the study period. We established different time periods for comparing the average hospitalizations per 100,000 inhabitants-year and the average stay, considering that the first biologic drug marketed for the treatment of psoriasis was in 2004. Results Regression models indicated a significant change in the temporal trend of the hospitalization rate per 100,000 inhabitants-year starting in 2004. In all cases, a gradual and significant decrease in the number of admissions per 100,000 inhabitants-year and in the average hospitalization rate per psoriasis per 100,000 inhabitants-year along the study period were found. There was also a significant decrease in medical hospitalizations and medical hospitalizations excluding psoriasis throughout the study period. Conclusions In our study population hospitalizations for psoriasis descended progressively and significantly from 2004. So far there are no extensive data on the impact of biological therapies on psoriasis hospitalization. J Drugs Dermatol. 2021;20(2):208-214. doi:10.36849/JDD.4931. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|